These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
587 related articles for article (PubMed ID: 28552710)
1. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. Tombal B; Cornel EB; Persad R; Stari A; Gómez Veiga F; Schulman C J Urol; 2017 Nov; 198(5):1054-1060. PubMed ID: 28552710 [TBL] [Abstract][Full Text] [Related]
2. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703 [TBL] [Abstract][Full Text] [Related]
3. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697 [TBL] [Abstract][Full Text] [Related]
4. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136 [TBL] [Abstract][Full Text] [Related]
5. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Sartor O; Gomella LG; Gagnier P; Melich K; Dann R Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455 [TBL] [Abstract][Full Text] [Related]
6. Intermittent versus continuous androgen deprivation in prostate cancer. Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669 [TBL] [Abstract][Full Text] [Related]
7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer. Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406 [TBL] [Abstract][Full Text] [Related]
8. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139 [TBL] [Abstract][Full Text] [Related]
9. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Eggener S Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673 [TBL] [Abstract][Full Text] [Related]
10. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678 [TBL] [Abstract][Full Text] [Related]
11. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25. Trump DL Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086 [TBL] [Abstract][Full Text] [Related]
12. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. Pathak AS; Pacificar JS; Shapiro CE; Williams SG J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298 [TBL] [Abstract][Full Text] [Related]
13. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876 [TBL] [Abstract][Full Text] [Related]
14. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Leibowitz RL; Tucker SJ Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience. Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893 [TBL] [Abstract][Full Text] [Related]
16. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591 [TBL] [Abstract][Full Text] [Related]
17. A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. Shore N; Mincik I; DeGuenther M; Student V; Jievaltas M; Patockova J; Simpson K; Hu CH; Huang ST; Li Y; Lee Y; Chien B; Mao J World J Urol; 2020 Jan; 38(1):111-119. PubMed ID: 30941562 [TBL] [Abstract][Full Text] [Related]
18. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Trachtenberg J; Gittleman M; Steidle C; Barzell W; Friedel W; Pessis D; Fotheringham N; Campion M; Garnick MB; J Urol; 2002 Apr; 167(4):1670-4. PubMed ID: 11912385 [TBL] [Abstract][Full Text] [Related]
19. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
20. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F; J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]